RxDoctor Payments Data

Dorothy Hite, PA

Medical · The Villages, FLNPI 1598737793

Payments from drug & device makers

$6,486in general payments, 2019–2025

Across 248 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$1K
  • AbbVie$795
  • Sun Pharmaceutical Industries Inc.$750
  • Johnson & Johnson$500
  • Sanofi$488
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$64810%
  • Food & beverage$5,36183%
  • Education$4787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,486 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$364,387
Medicare patients
812
Services billed
6,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$287,211
Cosentyx Unoready PenSecukinumab18$220,386
Humira(Cf) PenAdalimumab18$144,584
Dupixent PenDupilumab25$94,465
OtezlaApremilast14$79,961
Clobetasol Propionate190$7,287
Ketoconazole345$6,035
Fluorouracil39$3,101
Doxycycline Monohydrate146$3,083
Triamcinolone Acetonide316$2,999
Metronidazole36$2,156
Clindamycin Phosphate67$1,876
Mometasone Furoate51$1,028
Tretinoin11$932
Ciclopirox22$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$211$79,96114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.

Other medical in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →